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Aims: Establishing a balance between the benefits and harms of treatment is important
among individuals with screen-detected diabetes, for whom the burden of treatment might
be higher than the burden of the disease. We described the association between cardio-
protective medication and health-related quality of life (HRQoL) among individuals with
screen-detected diabetes.
Methods: 867 participants with screen-detected diabetes underwent clinical measurements
at diagnosis, one and five years. General HRQoL (EQ5D) was measured at baseline, one- and
five-years, and diabetes-specific HRQoL (ADDQoL-AWI) and health status (SF-36) at one and
five years. Multivariable linear regression was used to quantify the association between
change in HRQoL and change in cardio-protective medication.
Results: The median (IQR) number of prescribed cardio-protective agents was 2 (1 to 3) at
diagnosis, 3 (2 to 4) at one year and 4 (3 to 5) at five years. Change in cardio-protective
medication was not associated with change in HRQoL from diagnosis to one year. From one
year to five years, change in cardio-protective agents was not associated with change in the
SF-36 mental health score. One additional agent was associated with an increase in the
SF-36 physical health score (2.1; 95%CI 0.4, 3.8) and an increase in the EQ-5D (0.05; 95%CI 0.02,
0.08). Conversely, one additional agent was associated with a decrease in the ADDQoL-AWI
(0.32; 95%CI 0.51, 0.13), compared to no change.
Conclusions: We found little evidence that increases in the number of cardio-protective
medications impacted negatively on HRQoL among individuals with screen-detected dia-
betes over five years.
# 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Type 2 diabetes is associated with increased risk of morbidity
and early mortality [1] and a reduced health related quality of
life (HRQoL) [2]. Pharmacological management of individuals
with established diabetes reduces cardiovascular risk [3].
However, treatment regimens may impact on a patient’s
illness experience and their HRQoL and interventions that
improve cardiovascular risk factor levels do not necessarily
improve HRQoL [4]. Establishing a balance between the
benefits and harms of pharmacological treatment is particu-
larly important among individuals with screen-detected
diabetes, for whom the burden of treatment might be higher
than the burden of the disease [5,6]. The advent of national
screening programmes, such as the NHS Health Checks,
means that more people with clinically asymptomatic diabe-
tes will be diagnosed. There is limited research examining
how the burden of treatment might affect HRQoL for
individuals identified earlier in the diabetes disease trajectory.
Among patients with established diabetes, most research
supports an inverse association between glycosylated hae-
moglobin (HbA1C) and diabetes-related QoL [7,8]. In a cohort of
individuals with screen-detected diabetes, we recently
showed that people whose HbA1C decreased from one to five
years post-diagnosis were less likely to report a negative
impact of diabetes on their HRQoL [9]. However, further
research is needed to elucidate the relationship between
cardio-protective medication and HRQoL. This information
would help inform diabetes management strategies early in
the diabetes disease trajectory.
Among 867 participants with screen-detected diabetes (the
ADDITION-Cambridge trial cohort), we described the associa-
tion between (i) change in cardio-protective medication from
diagnosis to one year and change in general HRQoL (EQ-5D)
and (ii) change in cardio-protective medication from one to
five years and change in general (EQ-5D, SF-36) and diabetes-
specific HRQoL (ADDQoL-AWI). Our secondary aim was to
establish whether change in cardio-protective medication in
the first year after diagnosis was associated with changes
in HRQoL from one to five years.
2. Methods
We used data from the Cambridge centre of the ADDITION-
Europe trial [10], a pragmatic cluster randomised controlled
trial comparing intensive multifactorial treatment with
routine care in a screen-detected diabetes population in
primary care [11]. The study protocol has been published [10].
Individuals aged 40 to 69 years from 49 practices in Eastern
England, not known to have diabetes, and with a diabetes risk
score derived from practice records [12] corresponding to the
top 25% of the population distribution were invited for
stepwise screening. Exclusion criteria were pregnancy, lacta-
tion, an illness with a likely prognosis of less than one year or a
psychiatric illness likely to limit study involvement or
invalidate informed consent. 867 patients were found to have
diabetes according to 1999 WHO diagnostic criteria [13] and
agreed to take part in the treatment trial. The study wasapproved by the Eastern Multi-Centre Research Ethics Com-
mittee (ref: 02/5/54) [10] and all participants provided written
informed consent.
2.1. Intervention
Individuals were treated according to the group to which their
practice was allocated: routine care according to national
guidelines [14] (n = 23) or intensive multifactorial treatment
(n = 26). In the intensive treatment arm, GPs were encouraged
through guidelines, educational meetings, and audits with
feedback to introduce a stepwise target-led drug treatment
regime to reduce hyperglycaemia, hypertension and hyperli-
pidaemia [10] based on the STENO-2 study [15]. The interven-
tion also included funding for practices to facilitate more
frequent contact, a recommendation to refer all participants to
a dietician, and theory based diabetes education materials for
participants.
2.2. Measurement and outcomes
Trained staff assessed patients’ health at baseline, one year
and five years and collected biochemical and anthropometric
data according to standard operating procedures. Self-report
questionnaires were used to collect information on socio-
demographic information, lifestyle habits and medication use.
Changes in biochemical measures and medication from
baseline to five-year follow-up have been reported previously
[11].
The EuroQol three level index score (EQ-5D) was adminis-
tered at diagnosis, one and five years. The EQ-5D assesses
health utility over five domains of health (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression),
each with three levels of functioning, which results in 243
health states with scores ranging from 0.594 to +1.00 (full
health) [16]. The Short Form Health Survey (SF-36) measures
health status and consists of 36 items over eight health
domains; it can be summarised into physical (PCS) and mental
health summary (MCS) scores that range from 0 to 100, with
higher scores indicating better health [17]. The Diabetes-
specific Audit of Diabetes Dependent Quality of Life (ADDQoL),
measures an individual’s perception of the impact of diabetes
on various aspects of their QoL, and can be summarised as an
average weighted index score (ADDQoL-AWI) that ranges from
-9 (negative impact) to +3 (positive impact) [18]. The SF-36 and
ADDQoL-AWI were collected at one and five years only. For the
purposes of brevity, health status, diabetes-related QoL and
HRQoL are treated as synonymous in the text.
Participants were encouraged to bring their repeat pre-
scription summaries to each health assessment to aid with the
completion of a health economics questionnaire [19], which
asks for information on all prescribed medication. Self-
reported medication was ATC coded [20] and grouped into
13 types of cardio-protective agent: aspirin; any statin; any
other lipid lowering medication; any ACE inhibitor; any
b-blocker; any calcium channel blocker; any diuretic; any
other blood pressure lowering medication; any thiazolidinedione;
any sulphonylurea; metformin; insulin; or any other glucose
lowering medication. Cardio-protective medication count was
defined as the total number of the 13 cardio-protective agents
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one and five years.
2.3. Statistical analysis
Individuals that died between diagnosis and one year (n = 8),
and one year and five years (n = 47), were excluded from the
analysis sample. Only cases with complete data were
included. Descriptive characteristics were described at base-
line, one year and five years using means, medians and
proportions. Differences in characteristics between partici-
pants with and without complete data were examined using
logistic regression.
To describe change in cardio-protective medication, data
were collapsed into three groups: (i) no change or a reduction
in the number of cardio-protective agents (0); (ii) an increase of
one cardio-protective agent (1); and (iii) an increase of 2
cardio-protective agents (2). The baseline EQ-5D score was
subtracted from one year to calculate the change in EQ-5D
from diagnosis to one year. One-year HRQoL measures were
subtracted from five-year measures to calculate change in
HRQoL from one to five years. Multivariable linear regression
was used to quantify the association between change in
cardio-protective medication and change in EQ-5D from
baseline to one year with standard errors adjusted for
clustering by practice. A multilevel model accounting for
individuals within practices was considered, but due to a lack
of heterogeneity explained by practice in the primary
analyses, it was rejected for a parsimonious model. All models
were adjusted for age at diagnosis, gender, 2004 English Index
of Multiple Deprivation (IMD) score [21], self-reported CVD at
baseline, ethnicity, baseline value of the HRQoL measure,
baseline HbA1C level, randomisation group and practice level
clustering. In a second series of linear regression models, we
examined the association between change in cardio-protec-
tive medication from one to five years and (i) change in EQ-5D;
(ii) change in SF-36 (physical and mental score) and (iii) change
in ADDQoL-AWI from one year to five years. We adjusted the
model for the same factors outlined above, as well as self-
reported CVD at one year.
In a secondary analysis, the association between change in
cardio-protective medication in the first year after diagnosis
and changes in HRQoL (EQ-5D, SF-36 and ADDQoL-AWI) from
one to five years was assessed in a linear model analogous to
the primary analysis.
Different versions of the ADDQoL were used (ADDQoL-18
and ADDQoL-19) at one and five years. The authors of the
ADDQoL state that the measure remains robust if up to six
items are removed [22]. We removed the following items from
the summary score as they differed between questionnaires:
‘holidays/leisure activities’, ‘travel/journeys’, ‘society/people
reaction’, ‘dependence’, ‘enjoyment of food’, and ‘closest
personal relationship’. The Cronbach’s alpha for the ADDQoL-
AWI un-weighted items that were constant across both
questionnaires at one- and five-year follow-up was 0.90 and
0.94, respectively. In addition, we included a sensitivity
analysis using a Paretian model [23] of the complete ADDQoL
questionnaires, which ignored the relative importance of
change, instead focusing on the four possible directions of
change. Four categories were derived; (A) increase in anyADDQoL domain, (B) no change across domains, (C) decrease
in any domain, (D) mixed change, and regressed in a
multinomial model that was analogous to the primary
analysis.
Four additional sensitivity analyses were undertaken.
Firstly, change in the number of medications was fitted as a
continuous variable, rather than a categorical variable.
Secondly, data points missing for ethnicity, IMD, change in
agents, baseline of HRQoL measure and change in the HRQoL
measure in the primary analysis were imputed 100 times using
chained equations to account for missingness. Thirdly, change
in energy intake (food frequency questionnaire derived kcal/
day) or physical activity (EPAQ2 [24]) after diagnosis might
have confounded the observations and were added to the
model as covariates. Lastly, interactions between randomisa-
tion group and change in medication were explored and the
main analysis was also repeated in only the routine care
group.
The ADDITION-Cambridge trial was powered to detect a
20% relative effect of intensive treatment on modelled CVD
risk, with 90% power at the 5% level of significance assuming
30% of participants were lost to follow up [10]. Statistical
analyses were completed in Stata 13 and figures using R 3.0.2.
3. Results
Eight hundred and sixty seven patients agreed to participate in
ADDITION-Cambridge and attended baseline measurement.
Eight (0.9%) participants died before one year follow up, and 55
(6%) before five year follow up (Table 1). The median (IQR)
value of the EQ-5D score at baseline for participants that were
included in the analysis was (0.85; 0.73, 1). This was higher
than the score for those who died and were excluded from the
analysis (0.73; 0.62, 1). Participants who did not have complete
data at five year follow-up reported lower levels of physical
activity (at baseline) than those who attended. There were no
other significant differences between those with complete
data at five years and those with missing data for baseline age,
sex, BMI, current smoker, self-reported previous CVD, health
status (EQ5-D) or number of cardio-protective agents. The
greatest amount of missing data at one and five years was for
the SF-36 (18%, 151/860 and 19%, 151/805, respectively).
Missing medication and HRQoL data at one and five years
was not clustered in the same individuals, leading to an
increased level of missing data in the complete case analysis
models (Table 2).
3.1. Change from baseline to one year
Four individuals (0.5%) reported being prescribed a glucose-
lowering agent before diagnosis (Table 1) (three metformin,
one a sulphonylurea). 24% of participants were taking a lipid-
lowering agent, 58% a blood pressure-lowering agent and 19%
aspirin at baseline. From diagnosis to one year there was an
increase in the median number of prescribed agents, from 2
(IQR 1, 3) to 3 (2, 4). At one year follow-up, 251 (34%) individuals
reported the same or a reduced number of prescribed cardio-
protective agents, 185 (25%) one additional agent and 295 (40%)
two or more agents. From baseline to one year, median EQ-5D
Table 1 – Participant characteristics of ADDITION-Cambridge cohort at baseline, one and five years.
Baseline One year Five Years
N (%) Value N (%) Value N (%) Value
Median age at diagnosis in
years (IQR)
867 (100%) 63 (56, 67) – – – –
% Male 867 (100%) 61% – – – –
Median IMD score* (IQR) 750 (87%) 11 (7, 18) – – – –
% White ethnicity 859 (99%) 96% – – – –
% Any lipid medication 865 (100%) 24% 849 (99%) 66% 782 (96%) 82%
% Any BP medication 865 (100%) 58% 849 (99%) 69% 782 (96%) 79%
% Any diabetes medication 865 (100%) 0.5% 849 (99%) 31% 782 (96%) 62%
% Aspirin medication 865 (100%) 20% 849 (99%) 35% 782 (96%) 44%
Median number of lipid
medications (IQR)
865 (100%) 0 (0, 0) 849 (99%) 0 (1, 0) 782 (96%) 1 (1, 1)
Median number of BP
medications (IQR)
865 (100%) 1 (0, 2) 849 (99%) 1 (0, 2) 782 (96%) 1.5 (1, 2)
Median number of diabetes
medications (IQR)
865 (100%) 0 (0, 0) 849 (99%) 0 (0, 1) 782 (96%) 1 (0, 1)
HbA1C > 53 mmol mol
1 (7%) and
not on any diabetes medication
791 (91%) 39% 726 (85%) 1% 683 (84%) 8%
Median HbA1C % (IQR) 846 (98%) 6.8 (6.3, 7.7) 692 (81%) 6.4 (6, 6.8) 765 (88%) 6.9 (6.4, 7.4)
Median HbA1C % (IQR) 846 (98%) 51 (45, 61) 692 (81%) 46 (42,51) 765 (88%) 52 (46, 57)
Median number reported
cardio-protective medications
(IQR)
867 (100%) 1 (0, 2) 849 (99%) 2 (1, 3) 782 (96%) 3 (2, 4)
Median EQ-5D index score (IQR) 852 (98%) 0.85 (0.73, 1) 739 (86%) 0.85 (0.73, 1) 663 (82%) 0.85 (0.73, 1)
Median SF-36 MCS (IQR) – – 709 (83%) 56 (48, 59) 660 (81%) 57 (51, 60)
Median SF-36 PCS (IQR) – – 709 (83%) 48 (39, 54) 660 (81%) 48 (36, 54)
Median ADDQoL-AWI (IQR) – – 721 (84%) 0.39 (1, 0.06) 669 (82%) 0.37 (0.11, 0.86)
% Had CVD event – – – – 866 (100%) 7%
% Alive 867 (100%) 100% 866 (100%) 99% 866 (100%) 94%
 = Data unavailable; BP = blood-pressure; HBA1c = glycosylated haemoglobin; EQ-5D = European Quality of Life Questionnaire; MCS = Mental
component score; PCS = Physical component score; ADDQoL-AWI = Audit of diabetes-dependent quality of life average weighted index;
IQR = interquartile range.
* Cambridgeshire county had a mean IMD score of 11.7 in 2004 (http://data.gov.uk/dataset/imd_2004).
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proportion of individuals (45%, 327/729) reported no change in
health utility (Fig. 1). There was no evidence for an association
between change in the number of cardio-protective medica-
tions and change in the EQ-5D score from baseline to one year
(Table 2).
3.2. Change from one to five years
From one to five years after diagnosis, use of any anti-
hypertensive agent increased from 69% to 79%; larger
increases were seen in the reporting of any lipid-lowering
agents (66% to 82%) and any glucose-lowering agents (31% to
62%). Aspirin use increased from 35% at one year, to 44% at five
years. At one and five years, a median total of 3 (IQR 2, 4) and 4
(IQR 3, 5) cardio-protective agents were reported, respectively.
Over the same time period, 219 (36%) individuals reported no
increase in cardio-protective medication, 192 (32%) one more
agent and 193 (32%) two or more additional cardio-protective
agents. At one year, the median ADDQoL-AWI score was 0.39
(IQR 1, 0.06), suggesting that the majority of individuals
reported a negative impact of diabetes on their HRQoL.
Consistent with the baseline to one year results, change in
EQ-5D, SF-36 and ADDQoL-AWI measures between one and five
years were distributed evenly around no change (Fig. 1). There
was no association between increases in cardio-protectivemedication and change in the SF-36 MCS score (Table 2).
Increasing cardio-protective medication was associated with
an increase in the SF36-PCS score, but the association was only
statistically significant for an increase of one agent (2.1; 95%CI
0.3, 4.0). Conversely, while an increase in one, or more than
one, agents was associated with an increase in the EQ-5D
index score, the relationship was only statistically significant
for one or more additional agents (0.05; 95%CI 0.02, 0.08). An
association in the opposite direction was observed between
change in cardio-protective medication and the ADDQoL-AWI
score: more than one additional agent was associated with a
statistically significant decrease in the ADDQoL-AWI score
(0.20; 95%CI 0.38, 0.02) (Table 2).
3.3. Secondary analyses
We found no associations between change in medication in
the first year after diagnosis, and subsequent change in EQ-5D,
SF-36 PCS and MCS, or ADDQoL-AWI from one to five years in
models that were adjusted for potential confounders and
HRQoL at one year.
3.4. Sensitivity analyses
When modelling cardio-protective medication as a continu-
ous variable, similar statistically non-significant associations
Table 2 – Associations between change in number of cardio-protective agents and HRQoL in ADDITION-Cambridge cohort.
Outcome measure n (%) Change in agents, relative to no change/decrease in agents
One more agent More than one additional
agent
b (95%CI) p-Value b (95%CI) p-Value
Complete case analysis (Primary)
DEQ-5D, 0 to 1 year 601 (70%) 0.02 (0.05, 0.01) 0.210 0.02 (0.05, 0.01) 0.253
DEQ-5D, 1 to 5 year 513 (63%) 0.02 (0.02, 0.05) 0.317 0.05 (0.02, 0.08) 0.004
DSF-36 MCS, 1 to 5 years 488 (60%) 0.5 (2.2, 1.2) 0.552 0.4 (1.9, 1.0) 0.536
DSF-36 PCS, 1 to 5 years 488 (60%) 2.1 (0.3, 4.0) 0.024 0.5 (1.4, 2.3) 0.632
DADDQoL-AWI, 1 to 5 years 510 (63%) 0.11 (0.36, 0.14) 0.380 0.20 (0.38, 0.02) 0.030
Imputed
DEQ-5D, 0 to 1 year 859 (100%) 0.03 (0.06, 0.05) 0.102 0.02 (0.06, 0.01) 0.102
DEQ-5D, 1 to 5 years 811 (100%) 0.01 (0.05, 0.03) 0.594 0.06 (0.02, 0.10) 0.007
DSF-36 MCS, 1 to 5 years 811 (100%) 0.1 (1.5, 1.3) 0.862 0.5 (2.0, 1.1) 0.541
DSF-36 PCS, 1 to 5 years 811 (100%) 2.1 (0.4, 3.8) 0.019 0.2 (1.6, 1.9) 0.832
DADDQoL-AWI, 1 to 5 years 811 (100%) 0.20 (0.44, 0.05) 0.116 0.32 (0.51,0.13) 0.002
Including DPA and DEnergy
DEQ-5D, 0 to 1 year 593 (69%) 0.02 (0.05,0.02) 0.277 0.02 (0.05, 0.01) 0.232
Routine care arm only
DEQ-5D, 0 to 1 years 301 (73%) 0.05 (0.10,0.00) 0.073 0.00 (0.05, 0.05) 0.976
DEQ-5D, 1 to 5 years 252 (66%) 0.02 (0.04,0.08) 0.458 0.03 (0.02, 0.08) 0.458
DSF-36 MCS, 1 to 5 years 242 (64%) 0.5 (1.6, 2.6) 0.636 0.2 (2.2, 1.8) 0.825
DSF-36 PCS, 1 to 5 years 242 (64%) 0.8 (3.0, 4.7) 0.759 0.2 (3.4, 3.1) 0.909
DADDQoL-AWI, 1 to 5 years 245 (64%) 0.18 (0.50, 0.15) 0.275 0.26 (0.49, 0.03) 0.028
b coefficients (95% confidence interval) from a linear regression model adjusted for age at diagnosis, gender, 2004 IMD, self-reported CVD at
baseline, ethnicity, baseline value of the HRQoL measure, randomisation group and practice level clustering.
D = Change; BP = blood-pressure; EQ-5D = European Quality of Life questionnaire MCS = Mental component score; PCS = Physical component
score; ADDQoL-AWI = Audit of diabetes-dependent quality of life average weighted index.
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Similarly, coefficients from models based on imputed data
replicated findings from the complete case analysis. There
was no evidence of an association between change in the
ADDQoL-AWI and cardio-protective medication in a multino-
mial analysis of no change against an increase, decrease or
mixed change across ADDQoL domain scores. Changes in
physical activity and energy intake in the year after diagnosis
did not influence the associations between change in HRQoL
and change in cardio-protective medication. Models analo-
gous to the primary analysis run in the routine care arm of
ADDITION-Cambridge suggested that treatment arms could
be merged. Likewise, no interactions between the randomisa-
tion group and change in agents were detected.
4. Discussion
We found little evidence that increases in the number of
cardio-protective medications impacted negatively on HRQoL
among individuals with screen-detected diabetes over five
years. The few significant associations that we did observe
were linked to clinically negligible changes in HRQoL
measures.
For the EQ-5D, the smallest change associated with a
clinically meaningful improvement in health status amongst
individuals with diabetes is between 0.058 and 0.158 [25], while
in the general population a change in the EQ-5D of >0.07 canindicate a potential clinically relevant change [26]. This
suggests that the increase in EQ-5D associated with change
in medication in our analysis, while statistically significant, is
not likely to be clinically meaningful. More complex is an
apparent decrease in diabetes-specific QoL associated with
more than one additional agent (0.20; 95%CI 0.38, 0.02). In
an Australian population of 14,439 people with diabetes the
mean difference in ADDQoL between those with and without
complications was 0.69 [27]. It remains unclear whether a
decrease of up to 0.38 in the ADDQoL, which ranges from 9 to
+3, is clinically relevant.
As ADDITION-Cambridge is a novel cohort of individuals
with screen-detected diabetes, few direct comparisons with
published literature are possible. Shortly after diagnosis, 43%
of individuals with screen-detected diabetes from the Hoorn
Study were prescribed anti-hypertensive medication, 17%
lipid lowering medication and 24% oral diabetes medication
[28]. Among middle aged populations with established diabe-
tes, the average number of prescribed cardio-protective
medications is between four and five [5,29]. Despite a
significant treatment burden, many individuals with estab-
lished diabetes remained untreated for CVD risk factors such
as blood pressure and cholesterol [29]. In ADDITION-Cam-
bridge, individuals reported a median of two (IQR 3, 4) cardio-
protective medication at diagnosis and four (IQR 3, 5) by five
year follow-up. This is likely due to the population being
diagnosed earlier in the disease trajectory. However, there was
still evidence of under-treatment in our cohort [30].
Fig. 1 – Distribution of change in quality of life measures by change in cardio-protective agents in ADDITION-Cambridge
cohort. D = Change; SF-36 MCS = SF36 mental health summary score; SF-36 PCS = SF36 physical health summary score;
ADDQoL-AWI = Audit of diabetes-dependent quality of life average weighted index.
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HRQoL than the general population [31,32], individuals with
screen-detected diabetes have better HRQoL than those with
clinically diagnosed diabetes at diagnosis [28]. There is limited
literature with which to compare our findings on change in
HRQoL among individuals with screen-detected diabetes as
most published research has been conducted in populations
with long-standing diabetes. Seppa¨la¨ et al, in a Finnish
population, found that SF-36 assessed HRQoL was lower in
the 91 individuals with undiagnosed diabetes than in those
with normal glucose tolerance [32]. Grandy et al. [33]
demonstrated a small decrease in mean EQ-5D index score
(0.031 SD 0.158) over a five year time period in people with an
average diabetes duration of nine years (SD 7.8) [33].
In terms of the association between medication and
HRQoL, Wexler et al reported an inverse association between
HRQoL and longer diabetes duration, prescription of more
than 7 medications, older age and being female [2]. Trial
evidence on the relationship between intensifying treatment
and HRQoL is generally under-reported [34]. The UKPDS trial,
which enrolled recently diagnosed individuals more than a
decade before addition, found no difference between individ-
uals with a conventional or intensified treatment protocol
[35]. The ACCORD trial, which included individuals withestablished diabetes and early CVD, concluded that there was no
HRQoL benefit from very intensive (HbA1C< 42 mmol mol
1 [6%])
over moderate glycaemic control (HbA1C 53–63 mmol mol
1
[7.0–7.9%]) [7]. In a trial analysis of the ADDITION-Europe
cohort, in which relatively small differences in treatment
intensity were achieved, there were no differences between
EQ-5D or SF-36 scores for individuals in the routine care and
intensive treatment groups [11]. In our observational analy-
sis, we found no consistent association between an increase
in medication and reduced HRQoL. While this suggests that
increasing the number of prescribed cardio-protective med-
ications does not impact negatively on quality of life among
individuals with screen-detected diabetes, more research in
populations with diabetes detected early in the disease
trajectory is needed to confirm this finding.
4.1. Strengths and limitations
ADDITION-Cambridge is a large cohort of individuals with
screen-detected diabetes and long-term follow-up. Standar-
dised measurements and high response rates at diagnosis, one
year and five years allowed the examination of changes in
treatment burden and HRQoL measures. In addition to disease
specific and general HRQoL measures after diagnosis, a unique
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before a screen diagnosis of diabetes. Participants were
encouraged to bring repeat prescription summaries, and we
collected self-report medication data using an adaption of a
validated questionnaire [19]. We computed the total number
of cardio-protective agents to describe treatment burden, a
method which applies equal weight to each agent. We did not
examine the potential differing effect of individual drugs on
HRQoL. Nor did we conduct pill counts or account for differing
doses of prescribed treatments. In the sensitivity analysis,
cardio-protective medication was explored as a continuous
variable and results did not differ; this suggests that collapsing
medication change into an ordered categorical variable did not
obscure a small change. The use of fewer questions from
the original ADDQoL questionnaire might have affected the
instrument’s sensitivity. However, the Cronbach’s alpha
indicated high reliability in the shortened ADDQoL-AWI
version at both time points (0.90 and 0.94). Our analysis was
conducted in the first five years after detection by screening.
This population was younger and closer to ideal health than
cohorts with established diabetes. The association between
treatment intensity and HRQoL could change as duration of
diabetes and age increases.
Only a general HRQoL measure (the EQ-5D) was measured
before individuals were diagnosed with diabetes. At baseline,
our population had a mean EQ-5D index score of 0.81 (SD 0.21;
median 0.85; IQR 0.73, 1). The average value for a general
British population aged 55–64 is 0.80 (SD 0.26) [36]. This
suggests individuals with screen detected diabetes have a
comparable HRQoL to the general public, which potentially
limits the ability of the EQ-5D to detect small changes in
HRQoL when many individuals may remain at ‘ideal health
(score of 1)’. However, the EQ-5D has demonstrated an ability
to distinguish between populations with and without different
complications of diabetes [37]. The difference in our estimates
for the EQ-5D, and SF-36 PCS, compared to the ADDQoL-AWI
and SF36 MCS, provide weak evidence that the association
between cardio-protective medication and mental HRQoL
differs from physical HRQoL. This finding is surprising as
qualitative interviews suggest that the initial process of being
screened and labelled with the condition of early detected
diabetes is more often seen as a positive ‘‘wake up call’’ than a
negative experience [38]. Further research is needed to
establish if there is a clinically or economically relevant
association.
We compared concurrent changes in cardio-protective
medication and HRQoL between two time points, which were
one and four years apart. This may hide short term changes in
the prescription of medications and HRQoL within these time
points. Understanding such changes would inform the
temporality of the association, but would require a much
finer resolution of prescription patterns and HRQoL over the
five year period.
5. Conclusion
We found little evidence that increases in cardio-protective
medication had an adverse impact on HRQoL in people with
screen detected diabetes. There was no association betweenchange in cardio-protective medication and the EQ-5D from
diagnosis to one year. The few observations we observed from
one to four years were small, in different directions, and the
changes in HRQoL were clinically negligible. Targeted man-
agement of CVD risk factors in diabetes improves cardiovas-
cular health [3]. Our results suggest that clinicians should not
be concerned that increasing the number of cardio-protective
medications will impact negatively on quality of life among
individuals with screen-detected diabetes.
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